Cancer drug tested as simple skin injection

NCT ID NCT07391670

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new way to give the cancer drug durvalumab—as an injection under the skin instead of through an IV. It will involve about 40 adults with certain advanced solid tumors, including lung and liver cancers. The main goals are to find a dose that works similarly to the IV version and to check how safe it is.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Fitzroy, 3065, Australia
Research Site

St Albans, 3021, Australia
Research Site

Woolloongabba, 4102, Australia
Research Site

Batumi, 6010, Georgia
Research Site

Tbilisi, 0112, Georgia
Research Site

Tbilisi, 0114, Georgia
Research Site

Brzozów, 36-200, Poland
Research Site

Koszalin, 75-581, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Olsztyn, 10-357, Poland
Research Site

Przemyśl, 37-700, Poland
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 5505, South Korea
Research Site

Tainan, 73657, Taiwan
Research Site

Taipei, 110, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taoyuan District, 333, Taiwan

Conditions

Explore the condition pages connected to this study.

SOLID TUMOURS